Alfimeprase

DRUG7 trials

Sponsors

ARCA Biopharma, Inc.

Conditions

Acute Ischemic StrokeArterial Occlusive DiseasesCatheter OcclusionCatheters, IndwellingPeripheral Vascular DiseasesThrombosisVenous Thrombosis

Phase 2

Trial of a Novel Fibrinolytic (Alfimeprase) to Clear Thrombosed Vascular Access Devices

CompletedNCT00073515

ARCA Biopharma, Inc.Catheters, Indwelling

Target: 115Updated: 2010-02-03

Alfimeprase for Thrombolysis in Acute Peripheral Arterial Occlusion

CompletedNCT00073554

ARCA Biopharma, Inc.Arterial Occlusive Diseases, Peripheral Vascular Diseases, Thrombosis

Start: 2003-06-30Target: 100Updated: 2009-12-17

Phase 2 Proof-of-Concept Study of the Safety and Efficacy of Alfimeprase to Rapidly Open Arteries and Restore Brain Function Following a Stroke

TerminatedNCT00499902

ARCA Biopharma, Inc.Acute Ischemic Stroke

Start: 2007-06-30End: 2008-05-31Updated: 2008-04-24

Phase 3

Study of Alfimeprase to Rapidly Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery on Leg Arteries

CompletedNCT00115999

ARCA Biopharma, Inc.Arterial Occlusive Diseases

Start: 2005-04-30End: 2007-02-28Target: 300Updated: 2008-01-15

Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Catheters

CompletedNCT00322270

ARCA Biopharma, Inc.Catheter Occlusion, Thrombosis, Venous Thrombosis

Start: 2006-01-31Updated: 2008-08-15

Study of Alfimeprase's Ability to Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery

TerminatedNCT00338585

ARCA Biopharma, Inc.Arterial Occlusive Diseases

Start: 2006-04-30End: 2007-03-31Target: 300Updated: 2008-01-15

Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Central Catheters

CompletedNCT00346424

ARCA Biopharma, Inc.Thrombosis, Venous Thrombosis

Start: 2005-09-30End: 2006-12-31Updated: 2008-08-14